NR1H4 and hilar cholangiocarcinoma: This study will help us explore new therapeutic targets for hilar cholangiocarcinoma according to the changes in FXR and explore the role of FXR agonists, such as GW4064, in the treatment of hilar cholangiocarcinoma.